Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silver, D. E.
Right arrow Articles by Ruggieri, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silver, D. E.
Right arrow Articles by Ruggieri, S.

Neurology, Vol 50, Issue 6 S18-S22, Copyright © 1998 by American Academy of Neurology

VIEWS & REVIEWS

Initiating therapy for Parkinson's disease

DE Silver and S Ruggieri
Scripps Memorial Hospital, La Jolla, CA, USA.

Accurate diagnosis and individualized assessment of the risks and benefits of available antiparkinsonian medications should guide initiation of treatment for patients with early Parkinson's disease (PD). In general, the goals of treatment for younger patients (less than age 60 years) are control of impairing symptoms, sparing of levodopa to minimize long-term complications, and consideration of neuroprotection. The primary initial medication choices for patients under age 50 years include selegiline, amantadine, and anticholinergic agents. Patients in their fifties may require a dopamine agonist in addition to or instead of selegiline to achieve adequate symptom control. If the desired response is still not achieved, sustained- release carbidopa-levodopa should be added, followed by adjunctive amantadine or anticholinergic therapy. For older patients (60 years and over), improvement of functional impairment is the primary goal. For these patients, a special concern is to avoid inducing or exacerbating cognitive impairment. Sustained-release carbidopa-levodopa is considered first-line treatment for these patients. Inadequate response can be handled by a trial of immediate-release carbidopa-levodopa and then addition of a dopamine agonist when maximum levodopa doses are reached. Anticholinergic agents, amantadine, and selegiline should be avoided because of their CNS effects.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Nakagawa, M. Ohgoh, Y. Nishizawa, and H. Ogura
Dopaminergic Agonists and Muscarinic Antagonists Improve Lateralization in Hemiparkinsonian Rats in a Novel Exploratory Y-Maze
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 737 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
G. Nicholson, A. C. Pereira, and G. M. Hall
Parkinson's disease and anaesthesia
Br. J. Anaesth., December 1, 2002; 89(6): 904 - 916.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.